PE20080772A1 - Nuevos derivados de bipiridina sustituidos y su uso - Google Patents
Nuevos derivados de bipiridina sustituidos y su usoInfo
- Publication number
- PE20080772A1 PE20080772A1 PE2007001207A PE2007001207A PE20080772A1 PE 20080772 A1 PE20080772 A1 PE 20080772A1 PE 2007001207 A PE2007001207 A PE 2007001207A PE 2007001207 A PE2007001207 A PE 2007001207A PE 20080772 A1 PE20080772 A1 PE 20080772A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- hydroxy
- amino
- hydroxyetoxy
- alcoxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE X E Y SON CADA UNO N, C-R6; R6 ES H, ALQUILO C1-C4; Z ES N-R7, O; R7 ES H, ALQUILO C1-C4, SUSTITUIDO O NO POR HIDROXI, ALCOXI C1-C4; R1 Y R2 SON CADA UNO H, ALQUILO C1-C6 SUSTITUIDO O NO POR HIDROXI, AMINO, ENTRE OTROS; R3 ES H, ALQUILO C1-C6 SUSTITUIDO O NO, UNA O DOS VECES POR OXO, HIDROXI, AMINO, ENTRE OTROS; R4 ES H, HALOGENO, ALQUILO C1-C4, ALCOXI C1-C4, SUSTITUIDOS O NO POR HASTA 3 VECES CON FLUOR; R5 ES ARILO C6-C10, HETEROARILO DE 5 A 10 MIEMBROS. SON COMPUESTOS PREFERIDOS: 2'-AMINO-6'-({[2-(4-CLOROFENIL)-1,3-TIAZOL-4-IL]METIL}TIO)-5-(2-HIDROXIETOXI)-2,4'-BIPIRIDIN-3',5'-DICARBONITRILO; 2'-({[2-(4-CLOROFENIL)-1,3-TIAZOL-4-IL]METIL}TIO)-6-(2-HIDROXIETOXI)-6'-PIRROLIDIN-1-IL-3,4'-BIPIRIDIN-3',5'-DICARBONITRILO; ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO Y/O PROFILAXIS DE HIPERTONIA, ENFERMEDAD CARDIACA CORONARIA, DISLIPIDEMIAS, SINDROME METABOLICO, ENTRE OTROS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006042143A DE102006042143A1 (de) | 2006-09-08 | 2006-09-08 | Neue substituierte Bipyridin-Derivate und ihre Verwendung |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20080772A1 true PE20080772A1 (es) | 2008-08-07 |
Family
ID=38896950
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2007001207A PE20080772A1 (es) | 2006-09-08 | 2007-09-07 | Nuevos derivados de bipiridina sustituidos y su uso |
Country Status (11)
Country | Link |
---|---|
US (2) | US8653109B2 (es) |
EP (1) | EP2066637A1 (es) |
JP (1) | JP5331693B2 (es) |
AR (1) | AR062630A1 (es) |
CA (1) | CA2662728C (es) |
CL (1) | CL2007002610A1 (es) |
DE (1) | DE102006042143A1 (es) |
PE (1) | PE20080772A1 (es) |
TW (1) | TW200823209A (es) |
UY (1) | UY30578A1 (es) |
WO (1) | WO2008028590A1 (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004042607A1 (de) | 2004-09-03 | 2006-03-09 | Bayer Healthcare Ag | Substituierte Phenylaminothiazole und ihre Verwendung |
DE102006056740A1 (de) | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung |
DE102006056739A1 (de) | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung |
DE102007035367A1 (de) | 2007-07-27 | 2009-01-29 | Bayer Healthcare Ag | Substituierte Aryloxazole und ihre Verwendung |
DE102007036076A1 (de) | 2007-08-01 | 2009-02-05 | Bayer Healthcare Aktiengesellschaft | Dipeptoid-Produgs und ihre Verwendung |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE102007061763A1 (de) * | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte azabicyclische Verbindungen und ihre Verwendung |
DE102007061764A1 (de) * | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Anellierte Cyanopyridine und ihre Verwendung |
DE102008013587A1 (de) * | 2008-03-11 | 2009-09-17 | Bayer Schering Pharma Aktiengesellschaft | Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung |
ES2428818T3 (es) * | 2008-05-29 | 2013-11-11 | Bayer Intellectual Property Gmbh | Dicianopiridinas sustituidas con 2-alcoxi y su uso |
DE102008062567A1 (de) | 2008-12-16 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | Dipeptoid-Prodrugs und ihre Verwendung |
AU2015272011C1 (en) * | 2009-01-29 | 2017-12-14 | Bayer Intellectual Property Gmbh | Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof |
DE102009006602A1 (de) * | 2009-01-29 | 2010-08-05 | Bayer Schering Pharma Aktiengesellschaft | Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs |
WO2011150286A2 (en) | 2010-05-26 | 2011-12-01 | Satiogen Pharmaceuticals,Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
DE102010030688A1 (de) | 2010-06-30 | 2012-01-05 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Dicyanopyridine und ihre Verwendung |
US20120058983A1 (en) | 2010-09-02 | 2012-03-08 | Bayer Pharma Aktiengesellschaft | Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension |
TW201636330A (zh) | 2011-05-24 | 2016-10-16 | 拜耳知識產權公司 | 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺 |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP3278796A1 (en) | 2011-10-28 | 2018-02-07 | Lumena Pharmaceuticals LLC | Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease |
EP3266457A1 (en) | 2011-10-28 | 2018-01-10 | Lumena Pharmaceuticals LLC | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
US9708293B2 (en) | 2012-10-18 | 2017-07-18 | Bayer Pharma Aktiengesellschaft | N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group |
CA2888371C (en) | 2012-10-18 | 2021-06-08 | Ulrich Lucking | 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group |
PE20151071A1 (es) | 2012-11-15 | 2015-08-19 | Bayer Pharma AG | Derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximina |
TW201418243A (zh) | 2012-11-15 | 2014-05-16 | Bayer Pharma AG | 含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物 |
BR112015023646A2 (pt) | 2013-03-15 | 2017-07-18 | Lumena Pharmaceuticals Inc | inibidores de ácidos biliares de reciclagem para tratamento de colangite esclerosante primária e doença inflamatória do intestino |
CN105228615A (zh) | 2013-03-15 | 2016-01-06 | 鲁美纳医药公司 | 用于治疗巴雷特食管和胃食管返流疾病的胆汁酸再循环抑制剂 |
EP3016945B1 (en) | 2013-07-04 | 2017-05-03 | Bayer Pharma Aktiengesellschaft | Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors |
JP2017508757A (ja) | 2014-03-13 | 2017-03-30 | バイエル ファーマ アクチエンゲゼルシャフト | スルホン基を含有する5−フルオロ−n−(ピリジン−2−イル)ピリジン−2−アミン誘導体 |
WO2015150273A1 (en) | 2014-04-01 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | Disubstituted 5-fluoro pyrimidine derivatives containing a sulfondiimine group |
AU2015243585B2 (en) | 2014-04-11 | 2019-08-01 | Bayer Pharma Aktiengesellschaft | Novel macrocyclic compounds |
WO2016059086A1 (en) | 2014-10-16 | 2016-04-21 | Bayer Pharma Aktiengesellschaft | Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group |
ES2720525T3 (es) | 2014-10-16 | 2019-07-22 | Bayer Pharma AG | Derivados fluorados de benzofuranil-pirimidina que contienen un grupo sulfona |
WO2018153900A1 (de) | 2017-02-22 | 2018-08-30 | Bayer Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit sglt-2-hemmern |
WO2018153897A1 (de) | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit hcn-kanal-hemmern |
WO2018153895A1 (de) | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit einem inhibitor der neutralen endopeptidase und/oder einem angiotensin ii rezeptor-antagonisten |
WO2018153898A1 (de) | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit mineralocorticoid-rezeptor-antagonisten |
WO2018153899A1 (de) | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit stimulatoren und/oder aktivatoren der löslichen guanylatcyclase (sgc) |
US11254690B2 (en) | 2017-03-28 | 2022-02-22 | Bayer Pharma Aktiengesellschaft | PTEFb inhibiting macrocyclic compounds |
CA3057891A1 (en) | 2017-03-28 | 2018-10-04 | Bayer Aktiengesellschaft | Novel ptefb inhibiting macrocyclic compounds |
CN111727183B (zh) | 2018-02-13 | 2023-12-29 | 拜耳公司 | 5-氟-4-(4-氟-2-甲氧基苯基)-n-{4-[(s-甲基磺亚胺酰基)甲基]吡啶-2-基}吡啶-2-胺用于治疗弥漫性大b细胞淋巴瘤中的用途 |
CN114072153A (zh) | 2019-02-12 | 2022-02-18 | 米鲁姆制药公司 | 用于治疗胆汁淤积的方法 |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4052510A (en) | 1974-12-18 | 1977-10-04 | Sandoz, Inc. | 4-alkyl-2,6-di(secondary or tertiary alkylamino) pyridines, compositions thereof and methods for treating diabetes and obesity |
TW299333B (es) | 1992-12-29 | 1997-03-01 | Takeda Pharm Industry Co Ltd | |
DK0765327T3 (da) | 1994-06-16 | 1999-11-29 | Pfizer | Pyrazolo- og pyrrolopyridiner |
DE4430638A1 (de) | 1994-08-29 | 1996-03-07 | Bayer Ag | Verwendung von substituierten 4-Phenyl-6-amino-nicotinsäurederivaten als Arzneimittel |
JPH09132529A (ja) | 1995-11-09 | 1997-05-20 | Ono Pharmaceut Co Ltd | 一酸化窒素合成酵素阻害剤 |
PL327938A1 (en) | 1996-01-17 | 1999-01-04 | Novo Nordisk As | Derivatives of 1,2,4-thiadiazine and 1,4-thiazine, their production and application |
JP4431638B2 (ja) | 1996-01-29 | 2010-03-17 | アメリカ合衆国 | ジヒドロピリジン―、ピリジン―、ベンゾピラン―オン―およびトリアゾロキナゾリン誘導体、それらの製造およびそれらのアデノシン受容体アンタゴニストとしての用途 |
JPH10324687A (ja) | 1997-02-19 | 1998-12-08 | Nippon Soda Co Ltd | ピロール化合物、製法および農園芸用殺菌剤 |
US6191280B1 (en) | 1997-05-30 | 2001-02-20 | Basf Aktiengesellschaft | Method for producing substituted thiopyridines |
HUP0003999A3 (en) | 1997-07-16 | 2003-03-28 | Novo Nordisk As | Fused 1,2,4-thiadiazine derivatives, their preparation, their use and pharmaceutical compositions containing them |
US6632823B1 (en) | 1997-12-22 | 2003-10-14 | Merck & Co., Inc. | Substituted pyridine compounds useful as modulators of acetylcholine receptors |
DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19947154A1 (de) * | 1999-10-01 | 2001-10-04 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
EP1261327B1 (en) | 2000-02-25 | 2005-04-27 | F.Hoffmann-La Roche Ag | Adenosine receptor modulators |
MXPA03000436A (es) | 2000-07-18 | 2003-06-24 | Yamanouchi Pharma Co Ltd | Medicamentos que compreden derivados de dicianopiridina. |
AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
JP2004515543A (ja) | 2000-12-11 | 2004-05-27 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 有害無脊椎動物を防除するためのキナゾリノン類およびピリジニルピリミジノン類 |
ES2257461T3 (es) | 2000-12-21 | 2006-08-01 | Bristol-Myers Squibb Company | Inhibidores de tiazolilo de tirosina quinasas de la familia tec. |
DE10110438A1 (de) | 2001-03-05 | 2002-09-19 | Bayer Ag | Substituierte 2-Oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10110754A1 (de) | 2001-03-07 | 2002-09-19 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10110747A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung |
DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE10115945A1 (de) | 2001-03-30 | 2002-10-02 | Bayer Ag | Substituierte 2-Carba-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10115922A1 (de) | 2001-03-30 | 2002-10-10 | Bayer Ag | Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10134481A1 (de) | 2001-07-16 | 2003-01-30 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung |
DE10238113A1 (de) | 2001-12-11 | 2003-06-18 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung |
JP2003183254A (ja) | 2001-12-20 | 2003-07-03 | Yamanouchi Pharmaceut Co Ltd | 2−アシルアミノ−3,5−ジシアノピリジン誘導体又はその塩 |
EP1506189A1 (en) | 2002-04-26 | 2005-02-16 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
EP1388342A1 (en) | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals |
JP2006501217A (ja) | 2002-08-12 | 2006-01-12 | スージェン・インコーポレーテッド | 新規キナーゼ阻害剤としての3−ピロリル−ピリドピラゾールおよび3−ピロリル−インダゾール |
WO2004054505A2 (en) | 2002-12-12 | 2004-07-01 | Pharmacia Corporation | Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors |
AR042667A1 (es) | 2002-12-26 | 2005-06-29 | Taisho Pharmaceutical Co Ltd | Derivados de pirrolopirimidina y pirrolopiridina sustituidos con un grupo amino ciclico |
TW200418829A (en) | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
AR045047A1 (es) | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
WO2005030129A2 (en) | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Quinoline potassium channel inhibitors |
AU2004289304A1 (en) | 2003-11-10 | 2005-05-26 | Synta Pharmaceuticals, Corp. | Pyridine compounds |
US20050182105A1 (en) | 2004-02-04 | 2005-08-18 | Nirschl Alexandra A. | Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function |
JP2008503443A (ja) | 2004-06-25 | 2008-02-07 | 大正製薬株式会社 | テトラヒドロピリジンで置換されたピロロピリミジン及びピロロピリジンの誘導体 |
JP2007161585A (ja) | 2004-06-25 | 2007-06-28 | Taisho Pharmaceut Co Ltd | 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体 |
DE102004032651A1 (de) | 2004-07-06 | 2006-02-16 | Bayer Healthcare Ag | Verwendung von substituierten 2-Thio-3,5-dicyano-4-phenyl-6-aminopyriden bei der Behandlung von Übelkeit und Erbrechen |
DE102004042607A1 (de) | 2004-09-03 | 2006-03-09 | Bayer Healthcare Ag | Substituierte Phenylaminothiazole und ihre Verwendung |
EP2316457A1 (en) | 2004-09-20 | 2011-05-04 | Xenon Pharmaceuticals Inc. | Pyridine derivatives for inhibiting human stearoyl-coa-desaturase |
JP2008534453A (ja) | 2005-03-24 | 2008-08-28 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 再灌流傷害および再灌流障害の処置のための置換2−チオ−3,5−ジシアノ−4−フェニル−6−アミノピリジンの使用 |
US7750015B2 (en) | 2005-05-17 | 2010-07-06 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
WO2007073855A1 (en) | 2005-12-23 | 2007-07-05 | Bayer Healthcare Ag | Use of adenosine a1 receptor agonists for the protection of renal cells against toxic effects caused by aminoglycosides during treatment of infectious diseases |
DE102006009813A1 (de) | 2006-03-01 | 2007-09-06 | Bayer Healthcare Ag | Verwendung von A2b/A1 Rezeptor Agonisten zur Modulation der Lipidspiegel |
AU2007246172A1 (en) | 2006-04-28 | 2007-11-08 | Avexa Limited | Integrase inhibitors 3 |
DE102006056740A1 (de) | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung |
DE102006056739A1 (de) | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung |
DE102007035367A1 (de) | 2007-07-27 | 2009-01-29 | Bayer Healthcare Ag | Substituierte Aryloxazole und ihre Verwendung |
DE102007036076A1 (de) | 2007-08-01 | 2009-02-05 | Bayer Healthcare Aktiengesellschaft | Dipeptoid-Produgs und ihre Verwendung |
DE102008013587A1 (de) | 2008-03-11 | 2009-09-17 | Bayer Schering Pharma Aktiengesellschaft | Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung |
DE102008062567A1 (de) | 2008-12-16 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | Dipeptoid-Prodrugs und ihre Verwendung |
DE102009006602A1 (de) | 2009-01-29 | 2010-08-05 | Bayer Schering Pharma Aktiengesellschaft | Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs |
-
2006
- 2006-09-08 DE DE102006042143A patent/DE102006042143A1/de not_active Withdrawn
-
2007
- 2007-08-30 EP EP07801993A patent/EP2066637A1/de not_active Withdrawn
- 2007-08-30 WO PCT/EP2007/007572 patent/WO2008028590A1/de active Application Filing
- 2007-08-30 CA CA2662728A patent/CA2662728C/en not_active Expired - Fee Related
- 2007-08-30 JP JP2009527038A patent/JP5331693B2/ja not_active Expired - Fee Related
- 2007-08-30 US US12/440,423 patent/US8653109B2/en not_active Expired - Fee Related
- 2007-09-03 AR ARP070103888A patent/AR062630A1/es not_active Application Discontinuation
- 2007-09-07 PE PE2007001207A patent/PE20080772A1/es not_active Application Discontinuation
- 2007-09-07 TW TW096133320A patent/TW200823209A/zh unknown
- 2007-09-07 UY UY30578A patent/UY30578A1/es not_active Application Discontinuation
- 2007-09-07 CL CL200702610A patent/CL2007002610A1/es unknown
-
2014
- 2014-02-07 US US14/175,719 patent/US20140155401A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
UY30578A1 (es) | 2008-05-02 |
JP5331693B2 (ja) | 2013-10-30 |
AR062630A1 (es) | 2008-11-19 |
CL2007002610A1 (es) | 2008-02-01 |
WO2008028590A1 (de) | 2008-03-13 |
CA2662728A1 (en) | 2008-03-13 |
US20100093728A1 (en) | 2010-04-15 |
JP2010502659A (ja) | 2010-01-28 |
TW200823209A (en) | 2008-06-01 |
US8653109B2 (en) | 2014-02-18 |
DE102006042143A1 (de) | 2008-03-27 |
US20140155401A1 (en) | 2014-06-05 |
CA2662728C (en) | 2015-03-31 |
EP2066637A1 (de) | 2009-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20080772A1 (es) | Nuevos derivados de bipiridina sustituidos y su uso | |
PE20091694A1 (es) | DERIVADOS POLISUSTITUIDOS DE 6-HETEROARIL-IMIDAZO[1,2-a] PIRIDINAS COMO MODULADORES DE LOS RECEPTORES NOT Y SU PREPARACION | |
RU2010119487A (ru) | Пиримидилиндолиновое соединение | |
PE20110409A1 (es) | Compuestos heterociclicos antiviricos | |
PE20090674A1 (es) | Compuestos multiciclicos | |
PE20080671A1 (es) | DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA | |
PE20081845A1 (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
PE20080677A1 (es) | Inhibidores de pirrolotriazina cinaza | |
PE20120031A1 (es) | Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1 | |
ATE388146T1 (de) | 1-isopropyl-2-oxo-1,2-dihydropyridin-3- carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor | |
PE20081532A1 (es) | Compuestos novedosos | |
PE20060479A1 (es) | Compuestos heteroaril-aril-ureas como inhibidores de la quinasa | |
CL2008002142A1 (es) | Compuestos derivados de 2-amino-6-({[2-(4-clorofenil)-1,3-tiazol-4-il]metil}tio)-4-[4-(2-hidroxietoxi) fenil] piridin-3,5-dicarbonitrilo; procedimiento de preparacion; composicion farmaceutica y uso en enfermedades cardiovasculares. | |
PE20091466A1 (es) | Derivados de 4,5-dihidro-oxazol-2-il-amina | |
PE20070790A1 (es) | Derivados de 2-aminopirimidina como moduladores de la actividad del receptor de histamina h-4 | |
PE20070585A1 (es) | Derivados de sulfonamida como activadores de glucoquinasa | |
NO20085176L (no) | Fenyl substituerte heteroaryl-derivater og andvendelse som anti-tumor agenter | |
PE20090290A1 (es) | Derivados de pirrolopiridina como inhibidores de bace | |
PE20060691A1 (es) | Serinamidas sustituidas por benzoilo | |
PE20070212A1 (es) | Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen | |
PE20110063A1 (es) | DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK | |
PE20110852A1 (es) | Antagonistas del receptor de orexina de isonicotinamida | |
PE20071094A1 (es) | Derivados 1-ortoflurofenil sustituidos 1,2,5-tiadiazolidindionas como inhibidores de ptpasa | |
PE20060625A1 (es) | Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina | |
PE20090982A1 (es) | Derivados de piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |